Skip to main content
Premium Trial:

Request an Annual Quote

Dx Focus: Roche's Cobas TaqMan HIV-1 Test 2.0


Roche this week announced the US availability of the Cobas TaqMan HIV-1 Test v2.0 for use with the High Pure System.

Approved by the US Food and Drug Administration in July, the test is based on the company's proprietary dual-target approach, and enables labs to combine the FDA-approved High Pure process for manual viral nucleic acid preparation with the Cobas TaqMan 48 automated real-time PCR analyzer for amplification and detection.

The assay targets two highly conserved regions of the HIV-1 genome and avoids any regions that are current drug targets, thus providing reliable test results even when mutations are present, Roche said.

The new test completes Roche's High Pure System, which also provides FDA-approved processes for manual specimen preparation for hepatitis C and hepatitis B testing via automated real-time PCR. Labs can now consolidate HIV-1 amplification and detection on the Cobas TaqMan 48 along with HCV and HBV viral load monitoring assays.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.